

Assessment of Thyroid Function in Patients with β -Thalassemia

THESIS

Submitted for Fulfillment of Master Degree
In

Clinical Hematology

By

Mohamed Mostafa Mohamed Ahmed EL Missiry
M.B.,B.Ch.

Under Supervision of

Prof. Dr. Alia Abd El Aziz Saad Ayad

Professor of Internal Medicine, Faculty of Medicine, Cairo
University

Prof. Dr.Hala Mohamed Zaki Raslan

Professor of Internal Medicine, National Research Centre

Prof. Dr. Mona Mohamed Hamdy Mahmoud

Assistant Professor of Pediatrics, Faculty of Medicine,
Cairo University

Faculty of Medicine

Cairo University

2010

ACKNOWLEDGMENT

First and foremost, my great praise and sincere thanks should be submitted to ALLAH, the kindest and the most merciful, for the kind and continuous support to me.

*I would like to express my deep thanks, appreciation and sincere gratitude. To **Prof. Dr. Alia Abd El Aziz Saad Ayad**, Professor of Internal Medicine, Faculty of Medicine, Cairo University, for her valuable supervision, guidance and advice.*

*I would like also to express my sincere thanks to **Prof. Dr. Hala Mohamed Zaki Raslan**, Professor of Internal Medicine, National Research Centre, to whom the words fail to express her great care, guidance, support and supervision on this thesis.*

*My deepest thanks to **Prof Dr. Mona Mohamed Hamdy Mahmoud** Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, for her supervision, guidance, care and for her great support concerning collecting data and evaluation of the patients.*

*My appreciation and thanks to **Dr. Omneya Abd el Mogeheb**, lecturer of Endocrinology, Department of Internal Medicine, National Research Center, for her valuable guidance, advice and supervision.*

*Thanks and regards to my supervisor **Dr. Mona Hamed, Ibrahim**, Lecturer of clinical pathology, National Research Centre, for her sincere encouragement and her*

great effort and support concerning the laboratory part of the thesis.

*I would like also to express my sincere thanks to **Dr. Ali Makhlouf**, Professor of Pediatrics, Faculty of Medicine, Cairo University, for his endless support, care and help concerning collecting data and clinical examination for the patients.*

*Also I would thank **Dr. Amina Abd El Salam Mahmoud** for her valuable support concerning statistical analysis.*

*I would thank **Dr Dalia Elmy** , **Miss Shaimaa Mohamed Mohamed** , **Miss Amal Mohamed Hassan**, **Mr Waheed** and all the staff in the Egyptian association of thalassemia for their support and help.*

I would like also to thank my professors and colleagues in the Hematology Department, Internal Medicine Department, Faculty of Medicine (Kasr El Aini), Cairo University.

Finally, I would thank my parents, my wife and family for their love and care.

Abstract

Objectives: In this study, we tried to assess thyroid function among thalassemia patients .

Patients and Methods: This cross sectional study was conducted on 50 β -thalassemia major and intermedia patients (24 males and 26 females). Age range 15-37 years (Mean 21.4 ± 5.8 years). Patient were subjected to full history taking including transfusional and chelation history, clinical examination, performing complete blood count, measuring serum ALT (Alanine transaminase) and AST (Aspartate transaminase), measuring serum ferritin, and thyroid profile evaluation by measuring FT3 (free triiodothyronine), FT4 (free thyroxine) and TSH (thyroid stimulating hormone) using Immulite analyzer by chemiluminescent immunometric assay.

Results: 12 (24%) cases out of 50 cases were diagnosed as primary hypothyroidism (increased serum TSH) one of these 12 cases had biochemical overt hypothyroidism (low FT4 and/or FT3, increased TSH) and the 11 other patients had subclinical hypothyroidism (normal FT4, FT3, increased TSH). No cases of central hypothyroidism nor hyperthyroid were detected. A weak positive correlation was found between TSH level and AST ($r=0.28$, $P<0.05$), accordingly, mean AST levels were also found to be high in hypothyroid patients than those euthyroid ones (mean AST of hypothyroid patients: 87.583 ± 70.760 , mean AST of euthyroid patients: 46.855 ± 29.731 , $p=0.006$). This AST elevation may be explained by the associated iron overload in the liver. No statistically significant correlation was found between thyroid functions and each of the following parameters: anthropometric measures , age, hemoglobin level, serum ferritin, frequency of blood transfusion and chelator types. Comparison between well & poorly chelated patients revealed that the difference was statistically significant in mean AST level ($p=0.003$) and ALT level ($p=0.003$) which were higher in poorly chelated groups than those who are well chelated . This result shows a negative correlation between increase in serum aminotransferases levels (ALT and AST) and well chelation. Also, Highly significant positive correlation was found between serum ferritin level and AST ($r=0.77$, $p<0.001$) and ALT ($r=0.77$, $p<0.001$)

Conclusion: Primary hypothyroidism is prevalent among thalassemia patients mostly in the form of subclinical hypothyroidism. Overt laboratory hypothyroidism was also reported. Accordingly, screening for thyroid dysfunction in β -thalassemia major and intermedia patients is mandatory for early detection, diagnosis and treatment of primary hypothyroidism.

Key words: Thalassemia -Thyroid – Hypothyroidism-Iron overload

LIST OF CONTENTS

Title	Page No.
List of abbreviations.....	I
List of figures.....	III
List of tables.....	V
Introduction.....	1
Aim of Work.....	3
Review of Literature.....	4
Chapter (1): Thalassemia	4
Chapter (2):Thyroid	66
Chapter (3): Thalassemia and Thyroid.....	93
Patients & Methods.....	102
Results	108
Discussion.....	136
Recommendations.....	153
Summary	155
References.....	159
Appendix.....	194
Arabic Summary.....	196

List of Abbreviations

α	Alpha
β	Beta
ALT	Alanine transaminase
AST	Aspartate transaminase
BMI	Body Mass Index
BMT	Bone Marrow Transplantation
DFO	Desferrioxamine
δ	Delta
ϵ	Epsilon
FT3	Free T3
FT4	Free T4
γ	Gamma
Hb	Hemoglobin
HPLC	High Performance Liquid Chromatography
LIC	Liver Iron Concentration
PLT	platelets
SD	Standard Deviation

TPO	Thyroid Peroxidase
TSH	Thyroid Stimulating Hormone
ζ	Zeta

List of Figures

Figure number	Title
1	World genetic distribution of β -thalassmia
2	X-ray showing hair on end appearance
3	Iron overload
4	Electrophoresis
5	Measuring LIC by MRI for a thalassemia major patient.
6	The thyroid gland
7	Physiology of thyroid gland
8	The Sex Distribution of the Studied Cases
9	Frequency Distribution of Cases According to the Chelation Therapy
10	The incidence of hypothyroidism
11	Comparison of the hypothyroid patients (Group A) and the euthyroid (Group B) patients as regard Type of iron chelators.

12	Comparison of Mean Hemoglobin Level (g/dL) of the hypothyroid patients (Group A) and the euthyroid (Group B).
13	Comparison of Mean AST (IU/L) of the hypothyroid patients (Group A) and the euthyroid (Group B).
14	Comparison of Mean serum Ferritin (ng/ml) of the hypothyroid (Group A) and the euthyroid (Group B) patients.
15	Percentage of well & poorly chelated among our studied population.
16	Comparison of Mean AST (IU/L) of the well chelated (Group 1) and the poorly chelated (Group 2).
17	Comparison of Mean ALT (IU/L) of the well chelated (Group 1) and the poorly chelated (Group 2).

List of Tables

Table number	Title
1	Hemoglobin types
2	Frequency of Blood Transfusion / Year in the Studied Patients
3	The Prevalence of splenectomized and non splenectomized cases
4	Frequency Distribution of Cases According to the Chelation Therapy
5	The Anthropometric Data of the Studied Cases
6	Hematological and Biochemistry Profile of the Studied Cases
7	The Thyroid Profile of the Studied
8	Frequency Distribution of the Studied Cases According to the Thyroid Status
9	The demographic, clinical and laboratory data of the patient with primary hypothyroidism
10	Comparison of the Sex Distribution of the hypothyroid and the euthyroid patients
11	Comparison of the percentage of splenectomized and non-splenectomized of the hypothyroid and the euthyroid patients:
12	Comparison of the thalassemia Syndrome of the hypothyroid patients and the euthyroid ones
13	Comparison of the Frequency of Blood Transfusion / Year of the hypothyroid and the euthyroid patients
14	Comparison of the hypothyroid patients and the euthyroid patients as regard Type of iron chelators
15	Comparison of Anthropometric data of the hypothyroid and the euthyroid Patients
16	Comparison of laboratory data of the hypothyroid and the euthyroid patients
17	Comparison of the demographic data of the well

	chelated (Group 1) and the poorly chelated (Group 2)
18	Comparison of Anthropometric data of of the well chelated (Group 1) and the poorly chelated (Group 2)
19	Comparison of the prevalence of splenectomy of the well chelated (Group 1) and the poorly chelated (Group 2)
20	Comparison of the thalassemia Subtype of the well chelated (Group 1) and the poorly chelated (Group 2)
21	Comparison of the Frequency of Blood Transfusion / Year of the well chelated (Group 1) and the poorly chelated (Group 2)
22	Comparison of the well chelated (Group 1) and the poorly chelated (Group 2) patients as regard Type of iron chelators
23	Comparison of laboratory data of the well chelated (Group 1) and the poorly chelated (Group 2)
24	Comparison of Thyroid Profile of the well chelated (Group 1) and the poorly chelated (Group 2)
25	Comparison of The prevalence of thyroid dysfunction among the well chelated (Group 1) and the poorly chelated (Group 2)
26	comparison of Anthropometric data of the three treatment groups
27	Comparison of Laboratory parameters of the three treatment groups
28	Comparison of The prevalence of thyroid dysfunction among the three treatment groups
29	Correlations of TSH level (μ IU/ml) and the Studied Patients' variables
30	Correlations of serum ferritin (ng/ml) and the studied patients' variables
31 a	Detailed Data of Patients (part 1)
31 b	Detailed Data of Patients (part 2)

INTRODUCTION

In recent years, with significant increase in the lifespan of patients with β -thalassemia major several authors reported a high incidence of endocrine abnormalities in children, adolescents and young adults suffering from thalassemia major. However the incidence of the various endocrinopathies changes among different series of the patients due to a mixture of reasons other than iron overloads **(Gulati et al., 2000)**.

The combination of transfusion and chelation therapy has dramatically extended the life expectancy of thalassemic patients who can now survive into their fourth and fifth decades of life. On the other hand, frequent blood transfusion in turn can lead to iron overload which may result in hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism and other endocrine abnormalities. **(Shamshirsaz et al., 2003)**

Primary hypothyroidism is one of the most frequent complications observed in patients suffering from thalassemia **(Filosa et al., 2006)**. Decreased thyroid hormone alter erythropoiesis aggravating anemia, also it affects cardiac functions causing left ventricular

INTRODUCTION

disfunction, cardiac failure and pericardial effusion. The patient's presentation may be asymptomatic, mild to overt hypothyroidism, **(Tsironi et al., 2006)**

Aim of Work

Assessment of the thyroid function in the patient with β -thalassemia major and intermedia, for early diagnosis and treatment of hypothyroidism caused by thalassemia.

CHAPTER 1

Thalassemia

In 1925, Thomas Cooley and Pearl Lee described a form of severe anemia, occurring in children of Italian origin and associated with splenomegaly and characteristic bone changes **(Cooley and Lee, 1925)**. Over the next decade, a milder form was described independently by several Italian investigators **(Rietti, 1925; Greppi, 1928 ; Mecheli et al., 1935)** Because all early cases were reported in children of Mediterranean origin, the disease was later termed thalassemia, from the Greek word for sea, *thalassa* **(Whipple and Bradford, 1936)**. Over the next 20 years, it became apparent that Cooley and Lee had described the homozygous or compound heterozygous state for a recessive mendelian disorder not confined to the Mediterranean, but occurring widely throughout tropical countries. In the past 20 years, the two important forms of this disorder, α - and β -thalassemia, resulting from the defective synthesis of the α - and β -globin chains of hemoglobin, respectively, have become recognized as the